The Journal of Immunology, Vol 155, Issue 6 2960-2971, Copyright © 1995 by American Association of Immunologists

ARTICLES

Activation and preferential expansion of rat cytotoxic (CD8) T cells in vitro and in vivo with a bispecific (anti-TCR alpha/beta x anti-CD2) F(ab')2 antibody

AL Tutt, R Reid, BS Wilkins and MJ Glennie
Lymphoma Research Unit, General Hospital, Southampton, United Kingdom.

We show that a bispecific F(ab')2 Ab (BsAb), which cross-links the TCR to CD2 ([anti-CD2 x anti-TCR]) and is highly mitogenic in vitro, also induces marked T cell activation and proliferation when given as a small single dose (50 to 100 micrograms) to rats. Interestingly, the proliferation appeared selective for CD8 cells, increasing this compartment more than 20 times over 72 h. This resulted in a three- to fourfold increase in spleen weight, with histologic evidence of T-zone and red pulp expansion by CD8+ blast cells. Such changes were in striking contrast to those seen after a similar amount of the parent IgG anti-TCR mAb, R73, which, while inducing a transient increase in CD25+ cells, failed to alter the lymphocyte composition. The mitogenic activity of the BsAb was totally dependent on its ability to cross-link CD2 and the TCR, hence a mixture of anti-CD2 and anti-TCR F(ab')2 fragments was without effect in vitro or in vivo. Unlike normal rat T cells or those taken from R73 IgG-treated rats, blood and splenic T cells recovered from BsAb-treated rats were highly cytotoxic against R73 hybridoma targets that express surface anti-TCR mAb and consequently trigger the lytic activity of activated CTL or a rat lymphoma line, LAMA (Thy-1+), using a second BsAb, [anti-TCR x anti-Thy- 1], to retarget the CTL. This latter assay provides the basis for a future two-stage targeting strategy for cancer immunotherapy in which a mitogenic BsAb would be given to patients to activate CTL nonspecifically, and then, at an appropriate time, a second BsAb [anti- TCR x antitumor] would be given to deliver activated cells to the tumor target cells.

This article has been cited by other articles:

				A. L. Tutt, L. O'Brien, A. Hussain, G. R. Crowther, R. R. French, and M. J. Glennie T Cell Immunity to Lymphoma Following Treatment with Anti-CD40 Monoclonal Antibody J. Immunol., March 15, 2002; 168(6): 2720 - 2728. [Abstract] [Full Text] [PDF]

				J. Honeychurch, A. L. Tutt, T. Valerius, I. A. F. M. Heijnen, J. G. J. Van de Winkel, and M. J. Glennie Therapeutic efficacy of Fcgamma RI/CD64-directed bispecific antibodies in B-cell lymphoma Blood, November 15, 2000; 96(10): 3544 - 3552. [Abstract] [Full Text] [PDF]

				C. Faveeuw, M. E. Di Mauro, A. A. Price, and A. Ager Roles of {alpha}4 integrins/VCAM-1 and LFA-1/ICAM-1 in the binding and transendothelial migration of T lymphocytes and T lymphoblasts across high endothelial venules Int. Immunol., March 1, 2000; 12(3): 241 - 251. [Abstract] [Full Text] [PDF]

				A. L. Tutt, R. R. French, T. M. Illidge, J. Honeychurch, H. M. McBride, C. A. Penfold, D. T. Fearon, R. M. E. Parkhouse, G. G. B. Klaus, and M. J. Glennie Monoclonal Antibody Therapy of B Cell Lymphoma: Signaling Activity on Tumor Cells Appears More Important Than Recruitment of Effectors J. Immunol., September 15, 1998; 161(6): 3176 - 3185. [Abstract] [Full Text] [PDF]